STADA Arzneimittel AG / Key word(s): Preliminary Results
28.02.2013 13:23
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc release
STADA: Preliminary figures 2012 demonstrate successful financial year -
dividend to increase by more than 35 percent
Bad Vilbel, February 28, 2013 - On the basis of the preliminary figures for
financial year 2012, today on February 28, 2013, the Executive Board of
STADA Arzneimittel AG has taken a resolution on the dividend proposal for
the past financial year. According to the proposal, the STADA Executive
Board recommends that the Supervisory Board propose to the next Annual
General Meeting on June 5, 2013 a dividend for financial year 2012 in the
amount of Euro 0.50 per common share (previous year: Euro 0.37) and thereby
35.1 percent more than in the previous year. At the same time, the
Executive Board has adopted a positive outlook for financial year 2013 and
has confirmed the Group's long-term prognosis envisaged for 2014.
According to preliminary Group key figures, Group sales in 2012 are
expected to have increased by 7 percent to Euro 1,837.5 million. All
reported key earnings figures of the Group are expected to have recorded
growth. Thereby, reported EBITDA is anticipated to have increased by 45
percent to Euro 323.8 million. EBITDA adjusted for one-time special effects
is estimated to have risen by 9 percent to Euro 367.5 million and thereby
reached a new record high in corporate history. Reported earnings per share
are anticipated to have recorded an increase to Euro 1.46 (previous year:
Euro 0.37). Adjusted for one-time special effects and non-operational
effects from the measurement of derivative financial instruments, earnings
per share are expected to be slightly above the level of the previous year
with Euro 2.50 (previous year: Euro 2.49). In view of the investments made
in larger acquisitions in financial year 2012, net debt is anticipated to
have risen to Euro 1,177.3 million as of the balance sheet date (December
31, 2011: Euro 900.3 million). The net debt to adjusted EBITDA ratio is
estimated to have amounted to 3.2 (previous year: 2.7). As compared to the
figure in the first nine months of 2012, which was still at 3.6, a
substantial improvement of this ratio was able to be made within a short
period.
In its overall assessment, the Executive Board, from today's perspective,
expects further growth of sales and earnings of the Group for financial
years 2013 and 2014. For adjusted EBITDA in financial year 2013, the
Executive Board anticipates the opportunity for another increase in the
high single-digit percentage area and therefore to achieve a new record
figure. In addition, the Executive Board affirms the long-term prognosis
envisaged for 2014, according to which Group sales of approximately Euro
2.15 billion, at an adjusted level, EBITDA of approximately Euro 430
million and net income of approximately Euro 215 million should be reached
at minimum.
STADA's final business results for 2012 will be published on March 21,
2013.
STADA Key Figures
<pre>
2012(approx. 2011 +/-
figures)
Group sales Euro 1,837.5 million Euro 1,715.4 +7%
million
EBITDA Euro 323.8 million Euro 223.2 million +45%
EBITDA, adjusted Euro 367.5 million Euro 337.2 million +9%
Net income Euro 86.5 million Euro 22.0 million >100%
Net income, adjusted Euro 147.9 million Euro 146.6 million +1%
Earnings per share Euro 1.46 Euro 0.37 >100%
Earnings per share, Euro 2.50 Euro 2.49 +0.4%
adjusted
</pre>
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / 61118
Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de
Or visit us in the Internet at www.stada.com.
28.02.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STADA: Preliminary figures 2012 demonstrate successful financial year - dividend to increase by more than 35 percent
| Source: EQS Group AG